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SUMMARY.-Pretreatment with Metopirone (40 mg.) or SKF 525-A (2 mg./
100 g. maternal body weight) protected against the embryotoxic and terato-
genic actions of 7-OHM-12-MBA (2-5 mg/100 g. maternal body weight) in the
Sprague-Dawley rat. At the doses administered SKF-525-A was a more
efficient protector than Metopirone. The adrenocorticolytic actions of7-OHM-
12-MBA inthe maternal adrenal glands were also preventedbythesecompounds
and a close correlation existed between the degree of protection ofthe maternal
adrenals and of the foetuses. It is suggested that the ultimate embryopathic
substance is a metabolite of 7-OHM-12-MBA.
7,12-Dimethylbenz(a)anthracene (DMBA) and its metabolite 7-hydroxy-
methyl-12-methylbenz(a)anthracene (7-OHM-12-MBA) are powerful adrenocorti-
colytic agents in the Sprague-Dawley rat (Boyland, Sims and Huggins, 1965;
Wheatley et al., 1966). These effects can be prevented by pretreatment with
2-methyl-1,2-bis-(3-pyridyl)-1-propanone (Metopirone, CIBA) (Currie, Helfenstein
and Young, 1962; Dao and Tanaka, 1963; Wong and Warner, 1964; Wheatley,
1968a), or with /8-diethylaminoethyldiphenyl-n-propyl acetate (SKF 525-A)
(Wheatley, 1968b), both ofwhich affect the metabolism ofDMBA and 7-OHM-12-
MBA by the liver; they also inhibit corticosteroid synthesis (Chart et al., 1958;
Huffman andAzarnoff, 1967).
Recently we described the embryopathic effects of DMBA and 7-OHM-12-
MBA in the Sprague-Dawley rat (Currie et al., 1970). Treatment with a single
intravenous dose of 7-OHM-12-MBA (2-5 mg./100 g. maternal body weight) at
day 8 of pregnancy produced 100% resorptions; the same dose at day 13 caused
characteristic axial skeleton malformations in 100% ofsurvivingfoetuses andthere
was no increase in the resorption rate. Here we report the results ofexperiments
which show that Metopirone and SKF 525-A prevent the embryopathic effects
of7-OHM-12-MBA.
MATERIALS AND METHODS
Non-parous female Sprague-Dawley rats, 200-300 g. in weight, were obtained
from Oxford Laboratory Animal Colonies, Bicester, Oxon. The male Sprague-
Dawley rats were bred in the Foresterhill Animal House, University ofAberdeen.PROTECTION FROM EMBRYOPATHIC EFFECTS
They were fed with Thompson modified rat cube containing 14% skimmed milk
(North-Eastern Agricultural Co-operative Society Ltd., Aberdeen), and water was
allowed ad libitum. The females were caged overnight with males and the
morning on which spermatozoa were found in the vaginal smears designated day 0
ofpregnancy. Laparotomy was performed 24 hours before treatment to confirm
pregnancy.
7-OHM-12-MBA, in crystalline form, was dissolved in olive oil (10 mg./ml.)
and emulsified with saline to give a final concentration of 3 mg./ml. of 30% oil
emulsion. A single intravenous injection of 2-5 mg./100 g. of maternal body
weight was given into a lateral tail vein at day 8 or day 13 ofpregnancy. Control
groups received an equivalent volume of 30% emulsion which contained no
hydrocarbon.
Metopirone, dissolved in olive oil (50 mg./ml.) was given 4 hours before treat-
mentwith 7-OHM-12-MBA, andnormallyin oneintraperitoneal injection (40 mg.);
to reduce the toxic effects two of the 8-day pregnant rats were given Metopirone
in simultaneous intraperitoneal (10 mg.) and subcutaneous (30 mg.) injections
before the 7-OHM-12-MBA. SKF 525-A, dissolved in sterile saline (2 mg./ml.),
was injected intraperitoneally (2 mg./100 g. maternal body weight) at day 8 or
day 13, 30 minutes before 7-OHM-12-MBA. The control groups received an
equivalent volume of olive oil or saline and 7-OHM-12-MBA or Metopirone or
SKF 525-A (seetables).
The mothers were killed with chloroform on day 20 of pregnancy. The
number of dead or resorbing foetuses was noted and the survivors measured and
weighed. All surviving foetuses were necropsied and at least two from each
litter fixed in 95% ethanol and the skeleton stained with alizarin red. The
placentae were weighed and the maternal adrenal glands fixed in 4% neutral
buffered formaldehyde. Paraffin sections were stained with haematoxylin and
eosin.
RESULTS
Day 8 treatment
The resorption rate in the groups treated with 7-OHM-12-MBA alone or
pretreated with olive oil or saline ranged from 88% to 100% (Table I). Pretreat-
ment with Metopirone or SKF 525-A before 7-OHM-12-MBA significantly reduced
the resorption rate to 34% and 2% respectively (in each case P < 0.001). In
the control groups that did not receive 7-OHM-12-MBA the resorption rate was
within normal limits (range 3% to 16%).
TABLE I.-Protection by Metopirone or SKF 525-A from Embryotoxic Effects
after Treatment with 7-OHM-12-MBA on Day 8 of Pregnancy
No. No. surviving
No. rats Total No. resorptions foetuses with
Pretreatment Treatment treated implantations (%) malformations
7-OHM-12-MBA 4 . 49 . 43 (88)* 4
Control emulsion . 3 . 38 . 6 (16)* . 0
Metopirone . 7-OHM-12-MBA . 4 . 50 . 17 (34)t . 5
Olive oil 7-OHM-12-MBA . 3 . 34 . 34 (100)t * 0
SKF 525-A . 7-OHM-12-MBA . 3 . 41 . 1 (2)t . 0
Saline . 7-OHM-12-MBA . 3 . 36 . 33 (92) . 3
Metopirone . - . 3 . 46 . 3 (7) * 0
SKF 525-A . - . 3 . 34 . 1 (3) . 0
*P < 04001. tP < 0-001. 5P < 0.001.
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The three surviving foetuses from the group pretreated with saline, and some
of those from the group pretreated with Metopirone (5/33) or treated only with
7-OHM-12-MBA (4/6), showed teratogenic effects. The malformations included
exencephaly, encephalocele, spina bifida, microphthalmia, cleft palate, facial
cleft, renal agenesis, eventration of abdominal viscera, talipes and kinked tail.
All the surviving foetuses of the group pretreated with SKF 525-A and all those
in the control groups that did not have 7-OHM-12-MBA were normal.
Day 13 treatment
With no pretreatment 7-OHM-12-MBA produced marked stunting (see Table
III), and a posterior encephalocele and a spina bifida extending to the thoracic
or lumbar level in 100% ofsurviving foetuses (Fig. 1, Table II). The alizarin red
preparations revealed incomplete development of the occipital and interparietal
bones and stunting and eversion of the vertebral arches; the ribs and the supra-
spinous portions of the scapulae were incompletely developed and in some cases
totally absent. All animals had a fairly severe cervico-thoracic lordosis.
TABLE II. Protection by Metopirone orSKF 525-Afrom the Teratogenic Effects
after Treatment with 7-OHM-12-MBA on Day 13 ofPregnancy
Number of " surviving " foetuses with
posterior
No. rats no visible encephalocele
Pretreatment Treatment treated abnormality and spina bifida
- . 7-OHM-12-MBA 5 0 55*
- . Control emulsion . 6 . 63 0*
Metopirone . 7-OHM-12-MBA . 5 61 Ot
Olive oil . 7-OHM-12-MBA . 5 . 0 53t
SKF 525-A . 7-OHM-12-MBA . 6 . 57 0
Saline . 7-OHM-12-MBA . 4 . 0 421
Metopirone . - . 5 . 61 0
SKF 525-A . 5 . 55 0
*P < 0 001. tP < 0 001. $P < 0 001.
Pretreatment with Metopirone or SKF 525-A was highly protective (in each
case P < 0.001) and none of the surviving foetuses showed any macroscopic
abnormalities. The alizarin red preparations, however, revealed that in many
of these foetuses skeletal development was incomplete: in most cases the osseous
defects were minimal and chiefly involved the interparietal and occipital bones of
the skull and the lower pairs of ribs. SKF 525-A was again more effective in its
protective action than Metopirone: less than half of the foetuses pretreated with
SKF 525-A showed minor skeletal defects whereas nearly two-thirds of the
Metopirone-pretreated group were affected. The resorption rate was within
normal limits (range 2% to 10%) in all groups and teratogenic effects were not
produced by Metopirone or SKF 525-A alone.
Foetal andplacentalweights
The litters treated on day 13 of pregnancy with 7-OHM-12-MBA showed
significant reductions in foetal and placental weights on day 20 (Table III).
Metopirone and SKF 525-A pretreatment significantly increased the foetal and
placental weights; the increase in placental weight was proportionately greater
than the corresponding increase in foetal weight.
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FIG. 1.-Foetus from 7-OHM-12-MBA-treated litter (left) showing marked stunting, a posterior
encephalocele and a spina bifida extending to the lumbar region. Control foetus on right.
x approx.2*5.
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TABLE III.-Effects of Metopirone or SKF 525-A Pretreatment on the Foetal and
Placental Weights at Day 20 after Treatment with 7-OHM-12-MBA on Day 13
ofPregnancy
Pretreatment
Metopirone
Olive oil
SKF 525-A
Saline
Metopirone
SKF 525-A
Mean foetal
weight
No. of g. ± S.E.
Treatment litters (No. weighed)
7-OHM-12-MBA . 5 . 2.60±0.13*
(45)
Controlemulsion . 6 . 3.64±0-16*
(50)
7-OHM-12-MBA . 5 3.02+0-18t
(51)
7-OHM-12-MBA 5 2-67+0*14t
(44)
7-OHM-12-MBA . 6 3 -08 0 261
(48)
7-OHM-12-MBA . 4 2-96±0.1211
(32)
5 3-6840- 12
(51)
* - 5 .358+0-15
(45)
*P < 0*001. tP < 0-001. tP < 0-02.
§P < 0 001. lIP z 0 1. TP < 0-001.
Mean placental
weight
mg. ± S.E.
(No. weighed)
328 ±12t
(55)
. 497±22t
(63)
. 458±35§
(61)
. 350±25§
(53)
. 470±61¶
(57)
. 323±181¶
(42)
531±25
(61)
523±20
(55)
Maternaladrenalglands
The maternal adrenal glands were assessed independently by three separate
observers. SKF 525-A pretreatment completely protected the adrenal from
7-OHM-12-MBA. With Metopirone, protection was less complete and nearly
one-third ofthe rats pretreated at day 8 or day 13 showed single scattered necrotic
cells or small foci ofnecrosis in the inner zones ofthe cortex. A close correlation
was found between the degree ofprotection ofthe maternal adrenal glands and the
protection ofthe foetuses.
DISCUSSION
Metopirone and SKF 525-A protect the Sprague-Dawley rat from the embryo-
toxic andteratogenic effects of7-OHM-12-MBA. Metopirone is less effective than
SKF 525-A, but the dose of SKF 525-A was related to the weight of the mothers
whereas a constant dose of Metopirone was given. The resorption rate in two of
the unprotected groups treated with 7-OHM-12-MBA at day 8 was somewhat less
(88% and 92%) than that expected from our previous findings (Currie et al., 1970).
Some or all of the surviving foetuses in these groups, and in the Metopirone-
pretreated group, were malformed. The types of malformation were similar to
those found at day 8 with lower doses of 7-OHM-12-MBA (Currie et al., 1970),
and it seems probable that some or all of the foetuses which resorb before term
are malformed.
The proportionately greater increase in the placental weight as compared
with foetal weight in the groups pretreated with Metopirone and SKF 525-A at
day 13 ofpregnancy is of interest. Robson and Sullivan (1966) have shown that
disturbances ofplacental function may play an important part in the teratogenic
actions of some compounds, and it is possible that 7-OHM-12-MBA may have
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significant effects on placental development and function at day 13 ofpregnancy.
Metopirone and SKF 525-A also protect against the adrenocorticolytic actions
of 7-OHM-12-MBA in the mature rat, and in our experiments there was a close
correlation between the degree of protection of foetuses and of the maternal
adrenal glands. It is also of interest that SKF 525-A protects the foetal adrenal
gland (Bird, Crawford and Currie, 1970). Prevention of the adrenocorticolytic
effects with these compounds is currently assumed by some workers to depend
only on their interference with the hepatic metabolism of 7-OHM-12-MBA.
Metopirone, an inhibitor of adrenal 1 1-,8 hydroxylation (Chart et al., 1958), is
thought to stimulate the drug-metabolizing enzyme systems of the liver micro-
somes thus enhancing the inactivation of 7-OHM-12-MBA (Boyland and Sims,
1967; Wheatley, 1968a). However, Jellinck and Garrett (1969), while confirming
the in vivo effectiveness of Metopirone in preventing DMBA-induced adrenal
necrosis, were unable to show any appreciable difference in the metabolism of
DMBA by liver extracts prepared from Metopirone-pretreated rats. By contrast
SKF 525-A is a potent inhibitor of the hepatic microsomal enzymes (Axelrod,
Leichtenthal and Brodie, 1954; Cooper, Axelrod and Brodie, 1954), and Huffman
andAzarnoff (1967) have shown that it also inhibits corticosteroid synthesis by the
rat adrenal gland. It is possible that the ultimate active adrenocorticolytic agent
may be formed within adrenocortical cells. Whatever the case it is virtually
certain that a metabolite of 7-OHM-12-MBA is the ultimate adrenocorticolytic
agent (Wheatley and Sims, 1969), and the results here reported indicate that the
ultimate embryopathic agent is also a metabolite of 7-OHM-12-MBA and not
7-OHM-12-MBA itself. It may be that the ultimate embryopathic agent is
formed within the affected foetal tissues, and it remains to be shown whether it
and the ultimate adrenocorticolytic agent are the same compound.
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